Alimangum2935

Van der Woude syndrome (VWS), an autosomal dominant condition associated with clefts of the lip and/or palate and lower lip pits, is caused by mutations in interferon regulatory factor 6 gene. It is reported to be the most common syndromic cleft worldwide. This case series presents the phenotypic characteristics and treatment outcomes in a group of 9 patients diagnosed with VWS.

A retrospective review was performed on records of patients given a diagnosis of VWS presenting to the Department of Plastic Surgery of Sohag University between July 2009 and November 2019. Data analyses included age and sex of affected patients, type of the cleft, associated anomalies, presence of lower lip pits, and history of lower lip pits/cleft in the family and treatment outcomes.

The study identified 9 patients (male = 2, female = 7). Age at first presentation ranged between 1 week and 7 years (mean = 1.3 years). Four patients had bilateral cleft lip and palate and 1 patient had unilateral cleft lip and palate (UCLP), whery palatal surgeries for velopharyngeal insufficiency in patients with VWS; this warrant further studies including control group of nonsyndromic cleft patients.Background Chronic wounds remain a challenge for the clinician and healthcare system. It is therefore vital for additional therapies that target steps involved in wound recalcitrance. Recently, topical timolol has shown promising results for use in wound healing. Objective The goal of this study was to assess timolol’s effectiveness in healing wounds of varying etiologies. Methods This multi-center series took place from 2016¬–2019 at the wound healing centers at the University of Miami Health System and the Veterans Affairs Northern California Healthcare. We identified all wound patients who received treatment with topical timolol maleate 0.5% for at least 4 weeks after failing previous treatments. Timolol drops at a dose of 1 drop per cm2 of wound area were instilled with dressing changes twice a day, once a day, every other day, or continuous application. Once they began the study, they stopped all concurrent therapies aside from standard of care. Healing outcomes were classified into 3 categories healed, defined as complete re-epithelialization of the wound and closure, improved, defined as decreasing wound size area (WSA), and worsening, defined as increasing WSA. Results We identified 39 patients, 32 males and 7 females that had a total of 55 chronic wounds of varying etiologies. Thirty-four of the wounds had completely healed, 15 wounds improved in WSA, 4 wounds were unchanged in WSA, and 2 wounds worsened in WSA. Conclusions In line with our previous experience, we found topical timolol to be a safe, cost-effective, and efficacious treatment for recalcitrant wounds of varying etiologies.Access to health information online has resulted in increased internet use to !nd medical education resources.1,2 The United States (US) population is comprised of 60.1% Whites, 18.5% Hispanics or Latinos, 13.4% Blacks or African Americans, with trends toward increasing diversity. Our objectives were to analyze skin color distributions on the American Academy of Dermatology (AAD) public education website.

Few studies have assessed the use of hyaluronic acid (HA) fillers for rejuvenating the hands and décolletage. VYC-17.5L is an HA filler with physical properties that may be well suited to these areas.

This was a prospective study of females undergoing VYC-17.5L treatment in the dorsum of both hands and the décolletage. All had ageing of the hands rated 3–4 on the Allergan Hand Volume Deficit Scale (AHVDS), and of the décolletage rated 3–5 using the Fabi–Bolton Chest Wrinkle Scale (FBCWS). Patients were initially treated with VYC-17.5L up to a maximum of 1.5 mL per hand and 3.0 mL in the décolletage; VYC-17.5L touch up was allowed at 1 month. Subjects were followed up for 12 months. The primary endpoint was the number of responders in each hand and the décolletage at 6 months, defined as a ≥ 1-point improvement on AHVDS or FBCWS.

Thirty-three patients were enrolled (mean age, 56.6 ± 9.9 years). Six-month response rates were 100% in each hand (AHVDS) and 96.9% in the décolletage (FBCWS). Mean improvements were statistically significant at all three sites (P<0.001). At 6 months, patient satisfaction using the Global Aesthetic Improvement Scale was high 81.3% rated their right and left hands as ‘improved’ or ‘much improved’; 65.6% rated their décolletage this way. Results were durable out to 12 months for all endpoints. There were no unexpected safety findings.

VYC-17.5L was effective and safe for correction of skin depressions of the hands and décolletage. J Drugs Dermatol. 2020;19(12) doi10.36849/JDD.2020.5524.

VYC-17.5L was effective and safe for correction of skin depressions of the hands and décolletage. J Drugs Dermatol. 2020;19(12) doi10.36849/JDD.2020.5524.

Elastin is an essential component of the dermis, providing skin with elasticity and integrity. Elastin and other dermal components are gradually lost through aging, sun damage, and following injury, highlighting a need to replace these components to repair the skin. Tropoelastin (TE) in monomeric form was previously shown to be utilized as a substrate by dermal fibroblasts during the production of elastin fibers in vitro.

To analyze coaccumulation of elastin and collagen and gene expression of biomarkers associated with elastin production, examine the ex vivo effects of recombinant human TE (rhTE) and hyaluronic acid (HA) on epidermal and dermal structures, and evaluate the in vivo response following intradermal injections of rhTE and HA.

Human dermal fibroblasts and 3-D skin patch models were cultured for in vitro analysis. Ex vivo analysis was performed using skin explants. Menin-MLL Inhibitor mouse In vivo studies were done in 6-week-old male CD Hairless rats. Different formulations of rhTE, soluble or crosslinked using derivatized HA (dHA), were tested and analyzed.

rhTE in monomeric form was utilized as a substrate by dermal fibroblasts during the production of branched elastin and fibrous collagen networks in vitro. Formulations of rhTE crosslinked with dHA demonstrated increased expression of hyaluronic acid synthase 1 and ex vivo results revealed increased moisture content and glycosaminoglycan (GAG) deposition versus dermal filler control. Intradermal rhTE‒dHA injection produced colocalized human‒rat elastin fibers in vivo.

These results suggest that the novel rhTE‒dHA matrix is an attractive material to support skin tissue repair.J Drugs Dermatol. 2020;19(12) doi10.36849/JDD.2020.5375.

These results suggest that the novel rhTE‒dHA matrix is an attractive material to support skin tissue repair.J Drugs Dermatol. 2020;19(12) doi10.36849/JDD.2020.5375.